[1] |
NOCENTINI G, GIUNCHI L, RONCHETTI S, et al. A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis[J]. Proc Natl Acad Sci U S A, 1997, 94(12): 6216-6221. DOI: 10.1073/pnas.94.12.6216.
|
[2] |
GURNEY AL, MARSTERS SA, HUANG RM, et al. Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR[J]. Curr Biol, 1999, 9(4): 215-218. DOI: 10.1016/s0960-9822(99)80093-1.
|
[3] |
KIM JD, CHOI BK, BAE JS, et al. Cloning and characterization of GITR ligand[J]. Genes Immun, 2003, 4(8): 564-569. DOI: 10.1038 /sj.gene.6364026.
|
[4] |
NOCENTINI G, RICCARDI C. GITR: A modulator of immune response and inflammation[J]. Adv Exp Med Biol, 2009, 647: 156-173. DOI: 10.1007/978-0-387-89520-8_11.
|
[5] |
RICCARDI C, RONCHETTI S, NOCENTINI G. Glucocorticoid-induced TNFR-related gene (GITR) as a therapeutic target for immunotherapy[J]. Expert Opin Ther Targets, 2018, 22(9): 783-797. DOI: 10.1080/14728222.2018.1512588.
|
[6] |
SHIMIZU J, YAMAZAKI S, TAKAHASHI T, et al. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance[J]. Nat Immunol, 2002, 3(2): 135-142. DOI: 10.1038/ni759.
|
[7] |
KOHM AP, PODOJIL JR, WILLIAMS JS, et al. CD28 regulates glucocorticoid-induced TNF receptor family-related gene expression on CD4+ T cells via IL-2-dependent mechanisms[J]. Cell Immunol, 2005, 235(1): 56-64. DOI: 10.1016/j.cellimm.2005.07.002.
|
[8] |
RONCHETTI S, ZOLLO O, BRUSCOLI S, et al. GITR, a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations[J]. Eur J Immunol, 2004, 34(3): 613-622. DOI: 10.1002/eji.200324804.
|
[9] |
KOHM AP, WILLIAMS JS, MILLER SD. Cutting edge: Ligation of the glucocorticoid-induced TNF receptor enhances autoreactive CD4+ T cell activation and experimental autoimmune encephalomyelitis[J]. J Immunol, 2004, 172(8): 4686-4690. DOI: 10.4049/jimmunol.172.8.4686.
|
[10] |
van OLFFEN RW, KONING N, van GISBERGEN KP, et al. GITR triggering induces expansion of both effector and regulatory CD4+ T cells in vivo[J]. J Immunol, 2009, 182(12): 7490-7500. DOI: 10.4049/jimmunol.0802751.
|
[11] |
RONCHETTI S, NOCENTINI G, BIANCHINI R, et al. Glucocorticoid-induced TNFR-related protein lowers the threshold of CD28 costimulation in CD8+ T cells[J]. J Immunol, 2007, 179(9): 5916-5926. DOI: 10.4049/jimmunol.179.9.5916.
|
[12] |
SNELL LM, MCPHERSON AJ, LIN GH, et al. CD8 T cell-intrinsic GITR is required for T cell clonal expansion and mouse survival following severe influenza infection[J]. J Immunol, 2010, 185(12): 7223-7234. DOI: 10.4049/jimmunol.0903080.
|
[13] |
PEDROZA-GONZALEZ A, ZHOU G, SINGH SP, et al. GITR engagement in combination with CTLA-4 blockade completely abrogates immunosuppression mediated by human liver tumor-derived regulatory T cells ex vivo[J]. Oncoimmunology, 2015, 4(12): e1051297. DOI: 10.1080/2162402X.2015.1051297.
|
[14] |
VENCE L, BUCKTROUT SL, FERNANDEZ CURBELO I, et al. Characterization and comparison of GITR expression in solid tumors[J]. Clin Cancer Res, 2019, 25(21): 6501-6510. DOI: 10.1158/1078-0432.CCR-19-0289.
|
[15] |
NOWAKOWSKA DJ, KISSLER S. Ptpn22 modifies regulatory T cell homeostasis via GITR upregulation[J]. J Immunol, 2016, 196(5): 2145-2152. DOI: 10.4049/jimmunol.1501877.
|
[16] |
MAHMUD SA, MANLOVE LS, SCHMITZ HM, et al. Costimulation via the tumor-necrosis factor receptor superfamily couples TCR signal strength to the thymic differentiation of regulatory T cells[J]. Nat Immunol, 2014, 15(5): 473-481. DOI: 10.1038/ni.2849.
|
[17] |
TIAN J, ZHANG B, RUI K, et al. The role of GITR/GITRL interaction in autoimmune diseases[J]. Front Immunol, 2020, 11: 588682. DOI: 10.3389/fimmu.2020.588682.
|
[18] |
CARRIER Y, WHITTERS MJ, MIYASHIRO JS, et al. Enhanced GITR/GITRL interactions augment IL-27 expression and induce IL-10-producing Tr-1 like cells[J]. Eur J Immunol, 2012, 42(6): 1393-1404. DOI: 10.1002/eji.201142162.
|
[19] |
WANG S, SHI Y, YANG M, et al. Glucocorticoid-induced tumor necrosis factor receptor family-related protein exacerbates collagen-induced arthritis by enhancing the expansion of Th17 cells[J]. Am J Pathol, 2012, 180(3): 1059-1067. DOI: 10.1016/j.ajpath.2011.11.018.
|
[20] |
KO K, YAMAZAKI S, NAKAMURA K, et al. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells[J]. J Exp Med, 2005, 202(7): 885-891. DOI: 10.1084/jem.20050940.
|
[21] |
SUKUMAR S, WILSON DC, YU Y, et al. Characterization of MK-4166, a clinical agonistic antibody that targets human GITR and inhibits the generation and suppressive effects of t regulatory cells[J]. Cancer Res, 2017, 77(16): 4378-4388. DOI: 10.1158/0008-5472.CAN-16-1439.
|
[22] |
MA J, FENG D, WEI Y, et al. Blockade of glucocorticoid-induced tumor necrosis factor-receptor-related protein signaling ameliorates murine collagen-induced arthritis by modulating follicular helper T cells[J]. Am J Pathol, 2016, 186(6): 1559-1567. DOI: 10.1016/j.ajpath.2016.02.010.
|
[23] |
OJA AE, BRASSER G, SLOT E, et al. GITR shapes humoral immunity by controlling the balance between follicular T helper cells and regulatory T follicular cells[J]. Immunol Lett, 2020, 222: 73-79. DOI: 10.1016/j.imlet.2020.03.008.
|
[24] |
PEDROS C, ALTMAN A, KONG KF. Role of TRAFs in signaling pathways controlling T follicular helper cell differentiation and T cell-dependent antibody responses[J]. Front Immunol, 2018, 9: 2412. DOI: 10.3389/fimmu.2018.02412.
|
[25] |
CLOUTHIER DL, ZHOU AC, WORTZMAN ME, et al. GITR intrinsically sustains early type 1 and late follicular helper CD4 T cell accumulation to control a chronic viral infection[J]. PLoS Pathog, 2015, 11(1): e1004517. DOI: 10.1371/journal.ppat.1004517.
|
[26] |
KOH CH, KIM IK, SHIN KS, et al. GITR agonism triggers antitumor immune responses through IL21-expressing follicular helper T cells[J]. Cancer Immunol Res, 2020, 8(5): 698-709. DOI: 10.1158/2326-6066.CIR-19-0748.
|
[27] |
KIM IK, KIM BS, KOH CH, et al. Glucocorticoid-induced tumor necrosis factor receptor-related protein co-stimulation facilitates tumor regression by inducing IL-9-producing helper T cells[J]. Nat Med, 2015, 21(9): 1010-1017. DOI: 10.1038/nm.3922.
|
[28] |
KRAUSZ LT, BIANCHINI R, RONCHETTI S, et al. GITR-GITRL system, a novel player in shock and inflammation[J]. Scientific-WorldJournal, 2007, 7: 533-566. DOI: 10.1100/tsw.2007.106.
|
[29] |
NARDELLI B, ZARITSKAYA L, MCAULIFFE W, et al. Osteostat/tumor necrosis factor superfamily 18 inhibits osteoclastogenesis and is selectively expressed by vascular endothelial cells[J]. Endocrinology, 2006, 147(1): 70-78. DOI: 10.1210/en.2005-0518.
|
[30] |
LACAL PM, PETRILLO MG, RUFFINI F, et al. Glucocorticoid-induced tumor necrosis factor receptor family-related ligand triggering upregulates vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 and promotes leukocyte adhesion[J]. J Pharmacol Exp Ther, 2013, 347(1): 164-172. DOI: 10.1124/jpet.113.207605.
|
[31] |
AGOSTINI M, CENCI E, PERICOLINI E, et al. The glucocorticoid-induced tumor necrosis factor receptor-related gene modulates the response to Candida albicans infection[J]. Infect Immun, 2005, 73(11): 7502-7508. DOI: 10.1128/IAI.73.11.7502-7508.2005.
|
[32] |
GROHMANN U, VOLPI C, FALLARINO F, et al. Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy[J]. Nat Med, 2007, 13(5): 579-586. DOI: 10.1038/nm1563.
|
[33] |
LEE HS, SHIN HH, KWON BS, et al. Soluble glucocorticoid-induced tumor necrosis factor receptor (sGITR) increased MMP-9 activity in murine macrophage[J]. J Cell Biochem, 2003, 88(5): 1048-1056. DOI: 10.1002/jcb.10456.
|
[34] |
BAE E, KIM WJ, KANG YM, et al. Glucocorticoid-induced tumour necrosis factor receptor-related protein-mediated macrophage stimulation may induce cellular adhesion and cytokine expression in rheumatoid arthritis[J]. Clin Exp Immunol, 2007, 148(3): 410-418. DOI: 10.1111/j.1365-2249.2007.03363.x.
|
[35] |
BAE EM, KIM WJ, SUK K, et al. Reverse signaling initiated from GITRL induces NF-kappaB activation through ERK in the inflammatory activation of macrophages[J]. Mol Immunol, 2008, 45(2): 523-533. DOI: 10.1016/j.molimm.2007.05.013.
|
[36] |
WEI SD, LI JZ, LIU ZJ, et al. Dexamethasone attenuates lipopolysaccharide-induced liver injury by downregulating glucocorticoid-induced tumor necrosis factor receptor ligand in Kupffer cells[J]. Hepatol Res, 2011, 41(10): 989-999. DOI: 10.1111/j.1872-034X.2011.00852.x.
|
[37] |
WEI S, LI J, LIAN Z, et al. Expression of glucocorticoid-induced tumor necrosis factor receptor ligand in rat graft after liver transplantation[J]. Transplant Proc, 2011, 43(5): 1971-1975. DOI: 10.1016/j.transproceed.2011.03.054.
|
[38] |
WANG W, JI G, CHEN Y, et al. Changes in DNA methylation of glucocorticoid-induced tumor necrosis factor receptor and its ligand in liver transplantation[J]. Transplant Proc, 2017, 49(8): 1824-1833. DOI: 10.1016/j.transproceed.2017.06.023.
|
[39] |
LIAO G, O'KEEFFE MS, WANG G, et al. Glucocorticoid-Induced TNF receptor family-related protein ligand is requisite for optimal functioning of regulatory CD4(+) t cells[J]. Front Immunol, 2014, 5: 35. DOI: 10.3389/fimmu.2014.00035.
|
[40] |
LIAO G, NAYAK S, REGUEIRO JR, et al. GITR engagement preferentially enhances proliferation of functionally competent CD4+CD25+FoxP3+ regulatory T cells[J]. Int Immunol, 2010, 22(4): 259-270. DOI: 10.1093/intimm/dxq001.
|
[41] |
ZHANG HH, MEI MH, FEI R, et al. Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses[J]. J Viral Hepat, 2010, 17(Suppl 1): 34-43. DOI: 10.1111/j.1365-2893.2010.01269.x.
|
[42] |
ORMANDY LA, HILLEMANN T, WEDEMEYER H, et al. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma[J]. Cancer Res, 2005, 65(6): 2457-2464. DOI: 10.1158/0008-5472.CAN-04-3232.
|
[43] |
VAN BEEK AA, ZHOU G, DOUKAS M, et al. GITR ligation enhances functionality of tumor-infiltrating T cells in hepatocellular carcinoma[J]. Int J Cancer, 2019, 145(4): 1111-1124. DOI: 10.1002/ijc.32181.
|
[44] |
ZHOU G, SPRENGERS D, MANCHAM S, et al. Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules[J]. J Hepatol, 2019, 71(4): 753-762. DOI: 10.1016/j.jhep.2019.05.026.
|
[45] |
CABO M, OFFRINGA R, ZITVOGEL L, et al. Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications[J]. Oncoimmunology, 2017, 6(12): e1371896. DOI: 10.1080/2162402X.2017.1371896.
|